23 Aug 2023

Reference: CIR-2023-00000148

To all Health facilities / all health care practitioners in Dubai's private health sector

Referring to the above subject, DHA notifies all health facilities regarding the circular issued by the MOHAP for perusal and adhere to what is stated

Circular No.7422 for the year 2023 regarding field safety corrective action for medical devices

Suspension and Recall of the Medical Product Adakveo (crizanlizumab)

Thanks in advance for your good co-operation

Drug Control Section

Health Regulation Sector

DHA

Supporting Documents:

Adakveo (crizanlizumab ).pdf

download

FSN Weekly update 21 Aug 2023.pdf

download